购物车
您的购物车当前为空
Recaticimab (SHR-1209) 是一种人源化单克隆抗体,靶向 PCSK9。通过结合 PCSK9,Recaticimab 促进肝细胞 LDL 受体的稳定及表面表达,降低血浆 LDL 胆固醇水平。Recaticimab 正在作为高胆固醇血症及相关心血管疾病的化合物进行研究。
别名 瑞卡西单抗, SHR-1209, SHR1209
Recaticimab (SHR-1209) 是一种人源化单克隆抗体,靶向 PCSK9。通过结合 PCSK9,Recaticimab 促进肝细胞 LDL 受体的稳定及表面表达,降低血浆 LDL 胆固醇水平。Recaticimab 正在作为高胆固醇血症及相关心血管疾病的化合物进行研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,730 | 现货 | |
| 5 mg | ¥ 4,260 | 现货 | |
| 10 mg | ¥ 5,920 | 现货 | |
| 25 mg | ¥ 8,830 | 现货 | |
| 50 mg | ¥ 11,800 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders. |
| 别名 | 瑞卡西单抗, SHR-1209, SHR1209 |
| 反应种属 | Human |
| 应用 | ELISAFCMFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | Human IgG1 kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | PCSK9 |
| 分子量 | 148.41 kDa |
| CAS No. | 2361290-85-7 |
| 存储 | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多